Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Amortizatization of Intangibles (2023 - 2025)

Historic Amortizatization of Intangibles for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$201000.0.

  • CG Oncology's Amortizatization of Intangibles fell 11270.54% to -$201000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $710000.0, marking a year-over-year decrease of 9079.48%. This contributed to the annual value of $5.0 million for FY2024, which is 7363.48% up from last year.
  • Per CG Oncology's latest filing, its Amortizatization of Intangibles stood at -$201000.0 for Q3 2025, which was down 11270.54% from $1.9 million recorded in Q2 2025.
  • CG Oncology's Amortizatization of Intangibles' 5-year high stood at $2.5 million during Q2 2024, with a 5-year trough of -$1.3 million in Q4 2024.
  • In the last 3 years, CG Oncology's Amortizatization of Intangibles had a median value of $1.5 million in 2023 and averaged $1.1 million.
  • The largest annual percentage gain for CG Oncology's Amortizatization of Intangibles in the last 5 years was 3732.64% (2024), contrasted with its biggest fall of 18560.71% (2024).
  • Over the past 3 years, CG Oncology's Amortizatization of Intangibles (Quarter) stood at $1.5 million in 2023, then tumbled by 185.61% to -$1.3 million in 2024, then skyrocketed by 83.98% to -$201000.0 in 2025.
  • Its Amortizatization of Intangibles was -$201000.0 in Q3 2025, compared to $1.9 million in Q2 2025 and $279000.0 in Q1 2025.